BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28662671)

  • 1. Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.
    Będkowska GE; Gacuta E; Zajkowska M; Głażewska EK; Osada J; Szmitkowski M; Chrostek L; Dąbrowska M; Ławicki S
    J Ovarian Res; 2017 Jun; 10(1):39. PubMed ID: 28662671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.
    Będkowska GE; Ławicki S; Gacuta E; Pawłowski P; Szmitkowski M
    J Ovarian Res; 2015 May; 8():27. PubMed ID: 25935153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
    J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
    Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
    Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
    Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
    Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
    Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
    Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.